-
Product Insights
NewNeuroblastoma – Drugs In Development, 2024
Empower your strategies with our Neuroblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark...
-
Product Insights
NewMarginal Zone B-cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It's divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-001 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KB-001 in Alzheimer's Disease Drug Details: KB-001 is under development for the treatment of Alzheimer's...
-
Product Insights
Contrast Agents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Contrast Agents Pipeline Market Report Overview The Contrast Agents pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Positron Emitting Tomography Contrast Agents ·       Magnetic Resonance Imaging (MRI) Contrast Agents ·       Gadolinium-based MRI Contrast Agents...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zastaprazan in Corrosive Esophagitis (Erosive Esophagitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zastaprazan in Corrosive Esophagitis (Erosive Esophagitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zastaprazan in Corrosive Esophagitis (Erosive Esophagitis) Drug Details: Zastaprazan is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONC-392 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONC-392 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Metastatic Melanoma Drug Details: ONC-392 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – iopofosine i-131 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - iopofosine i-131 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Iopofosine I-131 in Solid Tumor Drug Details:Iopofosine I-131 (CLR-131) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Iopofosine I-131 in Brain TumorDrug Details:Iopofosine I-131 (CLR-131) is under development for...